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Background and aims: There is a growing body of literature conﬁrming the association between
inﬂammation and obesity. Recent research suggests that inﬂammation may play a role in weight gain.
The aim of the study was to analyse whether serum inﬂammatory markers predict weight gain or
development of obesity in a prospective study design.
Methods and results: The baseline study (DILGOM 2007) consists of a population-based sample of 5024
Finnish men and women aged 25e75 years, of whom 3735 participated in the follow-up study in 2014.
Baseline data collection included a questionnaire on health behaviour, physical examinations and blood
samples including serum high-sensitivity C-Reactive Protein (hs-CRP), Interleukin-1 receptor antagonist
(IL-1Ra), Interleukin-6 (IL-6), Tumor Necrosis Factor Alpha (TNF-alpha) and high molecular weight
adiponectin (HMW adiponectin). Indicators of obesity were weight, body mass index (BMI), waist
circumference and body fat percentage (% body fat). At baseline hs-CRP, IL-1Ra, IL-6, TNF-alpha and
HMW adiponectin associated strongly (p < 0.0001) with obesity indicators. After adjustment for several
potential predictors of obesity, hs-CRP and IL-1Ra associated inversely with changes in obesity indicators
during the 7-year follow-up. These associations disappeared, however, after further adjustment for
baseline BMI. Only HMW adiponectin retained a modest positive association with the change in weight
(p¼ 0.008), in BMI (p¼ 0.007) and in waist circumference (p¼ 0.002).
Conclusion: These ﬁndings suggest that the inﬂammatory markers, although highly associated with
obesity, do not predict weight gain in an adult population. This could translate into inﬂammation being a
result of obesity rather than a contributing factor to it.
© 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Obesity is a major public health challenge in the developed
world and increasingly also in the developing world [1,2].
Obesity and being overweight have been associated with low-
grade chronic inﬂammation [3e8]. Recent research suggest that
inﬂammation may play a role in the process of weight gain in
children [9] and in adults [10]. It has been a chicken and egglth and Welfare, P.O.Box 30,
isto), pekka.jousilahti@thl.ﬁ
inna), katja.borodulin@thl.ﬁ
ist€o), veikko.salomaa@thl.ﬁ
Inc. This is an open access article uquestion and no deﬁnitive results have been presented as to
whether subclinical inﬂammation actually is a cause or a conse-
quence of obesity. Accordingly, the roles of a variety of inﬂamma-
tion markers as predictors of weight gain are not clear.
Increased levels of markers of inﬂammation such as high
sensitivity C-Reactive Protein (hs-CRP), certain interleukins and
Tumor Necrosis Factor Alpha (TNF-alpha) have been linked with
metabolic disorders, cardiovascular diseases as well as an increased
risk of mortality [11e13]. Obesity also inﬂuences the development
of these outcomes. Better understanding of the link between
weight gain, obesity and the development of low-grade chronic
inﬂammation could prove useful in addressing these major public
health issues.
The aim of the study was to analyse whether subclinical
inﬂammation precedes and predicts obesity. The speciﬁc objectivender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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6), interleukin-1 receptor antagonist (IL-1Ra), TNF-alpha and
reduced levels of high molecular weight adiponectin (HMW adi-
ponectin) preceded weight gain, increasing body mass index (BMI),
increasing waist circumference and increasing body fat percentage.
2. Methods
2.1. Baseline survey and follow-up
The DILGOM (the DIetary, Lifestyle and Genetic determinants of
Obesity and Metabolic syndrome) study was conducted as an
extension of the National FINRISK 2007 Study in AprileMay 2007.
DILGOM 2007was the baseline study of a population-based sample
of men and women aged 25e75 years living in Finland (n¼ 5024,
participation rate 80%). Participants of the baseline study respon-
ded to questionnaires, underwent physical examination (including
anthropometric measures) by trained nurses and gave blood sam-
ples. Detailed study protocols, including the sampling, measure-
ments and blood sample protocols are described in detail
elsewhere [14,15]. The participant ﬂowchart for the baseline and
follow-up study has been published earlier [15] and can be viewed
online here: https://media.nature.com/original/nature-assets/ijo/
journal/v42/n4/extref/ijo2017278x2.pdf.
Seven years later, all living baseline study participants were
invited to participate in the DILGOM follow-up study in 2014 and
altogether 3735 participants (response rate 82%) returned the
survey questionnaire. A comparison of the characteristics between
participants and non-participants has been presented earlier [15].
Participants from the capital metropolitan area and South-
western Finland attended a health examination (n¼ 1312). During
the health examination, trained nurses measured weight, height,
waist circumference and body fat percentage. This examinationwas
carried out in the same spring months and following the same
standardized protocol as for the baseline examination. Blood
samples were drawn from the participants attending the health
examination. Participants who were not invited for a health ex-
amination (n¼ 2423) reported their current weight, height and
waist circumference; the latter was measured by the participants
themselves according to detailed written instructions received
together with a measurement tape. The self-reported measure-
ments have been validated against the measurements by trained
nurses [16]. Body fat percentage (% body fat) was measured with a
bioelectrical impedance instrument (TANITA TBF-300MA, Tanita
Corporation of America, Inc., Arlington Heights, IL, USA) [17].
Record linkages based on the personal identiﬁcation code to
Finnish National health care registers such as the Hospital
Discharge register and the National Causes-of-Death register were
used to identify subjects that needed to be excluded from the
analysis due to any prevalent or incident disease (detailed under
the Design section) relevant to weight change at baseline or during
follow-up.
The study plan for the DILGOM baseline examination was
approved by the Coordinating Ethical Committee of the Helsinki
and Uusimaa Hospital District on April 03, 2007. The decision
number is 229/E0/2006. The study plan for the re-examinationwas
approved by the same Ethical Committee on January 14, 2014. The
decision number is 332/13/03/00/2013. All participants signed an
informed consent.
2.2. Design
We analysed the DILGOM baseline and follow-up data (from the
questionnaires, physical examinations and blood samples) to
determine whether serum inﬂammation markers are associatedwith weight gain and development of obesity in the 7-year-follow-
up.
The main outcome measures were changes in weight (in kg),
BMI (kg/m2), waist circumference (cm) and body fat percentage
(%-unit) during the 7-year follow-up. The explanatory variables of
main interest were inﬂammatory markers hs-CRP, IL-1Ra, IL-6, and
TNF-alpha as well as the anti-inﬂammatory protein HMW
adiponectin.
Participants with established weight-loss causing diseases
prevalent at baseline or incident during the 7-year follow-up, such
as cancer (excluding ICD10 category C44), hyperthyroidism, HIV
and tuberculosis were excluded. Participants who were pregnant
either at baseline or at follow-up, were also excluded. In addition,
based on visual inspection of the outcome measure distributions,
three extreme outliers (one with 40.7 kg weight gain, one with
51.6 kg weight loss and one with 88.5 cm waist gain during the 7-
year follow-up) were excluded. Altogether 366 individuals were
excluded from the analyses. In total the study population included
3369 participants.
2.3. Laboratory methods
Concentrations of hs-CRP were measured from frozen serum
samples (70 C) using a latex immunoassay (Sentinel diagnostics,
Milan, Italy) on Architect c8000 analyzer (Abbott Laboratories,
Abbott Park, IL, USA), interleukin 6 and TNF-alpha concentrations
with multiplex sandwich immunoassays (Milliplex High Sensitivity
Human Cytokine kit, Millipore, Billerica, MA, USA) and IL-1Ra and
high molecular weight adiponectin concentrations using enzyme
linked immunosorbent assays (Human IL-1ra/IL-1F3 Quantikine
ELISA Kit, R&D Systems, Inc., Minneapolis, MN, USA and Human
HMW Adiponectin ELISA kit, Millipore, Billerica, MA, USA) for IL-
1Ra and HMW adiponectin, respectively. Hs-CRP measurements
of samples drawn at follow-up were conducted using the same
method as mentioned above.
2.4. Statistical methods
Means and standard deviations were calculated for normally
distributed continuous variables, geometrical means and anti-logs
of standard deviations are shown for continuous variables with a
skewed distribution and frequencies for categorical variables.
Welch Two Sample t-tests were used to compare baseline and
follow-up values.
We ran a residual analysis to determine the appropriateness of a
linear regression model for hs-CRP, Il1-Ra, IL-6, TNF-alpha and
HMW adiponectin. As a result of these analyses, we used log-
transformed inﬂammatory markers in linear regression analysis.
To enable comparison between the different inﬂammation
markers, we expressed the associations per one standard deviation
(SD) difference in log-transformed concentrations of the inﬂam-
mation markers.
Generalized linear regressionmodels were applied for analysing
cross-sectional and longitudinal associations between the explan-
atory variables and the obesity indicators. Conventional risk factors
for weight change and other relevant baseline characteristics such
as age, sex, education, smoking, alcohol consumption, energy
intake, physical activity at leisure time and BMI at baseline were
adjusted for in multivariable linear regression models. Age, alcohol
consumption, energy intake and BMI were used as continuous
variables whereas the remaining ones were categorical variables
(categories named in Table 1). For each analysis, outliers with a
difference of more than 3 standard deviations from the mean of the
inﬂammation marker level were excluded from the analysis. The
continuous outcome variables usedwere: change inweight, change
Table 1
Participant characteristics at baseline.
Baseline characteristics Women Men
(n¼ 1836) (n¼ 1533)
Age, years 51.4± 13.1 52.5± 12.8
Height, cm 162.5± 6.2 176.0± 6.7
Waist circumference, cm 86.1± 13.0 95.8± 11.3
Hip circumference, cm 101.3± 10.5 100.0± 7.2
Smoking, n (%)
Never smokers 1234 (67.5) 736 (48.2)
Ex-smokers 325 (17.8) 495 (32.5)
Current smokers 270 (14.8) 295 (19.3)
Educational status, n (%)
Low 577 (31.8) 392 (25.7)
Middle 608 (33.4) 549 (35.9)
High 632 (34.8) 586 (38.4)
Physical activity at leisure time, n (%)
Low level or no exercise 315 (17.2) 257 (16.8)
Light exercise, at least 4h per week 1025 (56.2) 787 (51.5)
Aerobic exercise, at least 3h per week 474 (26.0) 445 (29.1)
Regular exercise at competitive level 11 (0.6) 39 (2.6)
Total energy intake, MJ/day 9.7± 3.2 11.9± 4.0
Weekly alcohol intake, g/week 37.2± 64 86.9± 117
hs-CRP, mg/l 1.17 (1.78) 1.07 (1.51)
IL-1Ra, pg/ml 282 (182) 263 (143)
IL-6, ng/l 2.75 (3.73) 3.08 (4.18)
TNF-alpha, ng/l 5.21 (3.42) 6.03 (3.59)
HMW Adiponectin, ng/ml 4873 (4548) 2560 (2630)
Results are presented as means (standard deviation) and percentages, except for hs-
CRP, Il1Ra, IL-6, TNF-alpha and HMW adiponectin where geometric means (inter-
quartile range IQR) are reported.
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We also performed logistic regression for hs-CRP with BMI cut-
off points less than 30 kg/m2 and equal to or over 30 kg/m2 as an
outcome and for a cut-off point of 10% or more weight gain and less
than 10% weight gain during the 7-year follow-up as an outcome.
Finally, we performed the linear regression analyses for hs-CRP
using only never smokers.
Apart from the baseline characteristics, all results are presented
for analyses with women and men combined as there were no
differences in the results between the sexes. The analyses were
conducted using R 3.4.1 (R Core Team 2017) and RStudio 1.0.153.
3. Results
Baseline and follow-up characteristics are presented for men
and women in Tables 1 and 2. Average weight change during the 7-
year follow-up was 0.70 kg, with a minimum of 31.5 kg and
maximum of 31.9 kg. Notably, 10.4% (12.2% in women and 8.3% in
men) of the study population gained 10% or more of weight during
the 7-year follow-up.
3.1. Cross-sectional analyses
A linear regression analysis, accounting for age and sex, wasTable 2
Baseline and follow-up values of outcome variables.
Women at baseline (n¼ 1836) Women at follow-up
Weight, kg 70.0± 13.5 71.0± 14.0
Waist circumference, cm 86.1± 13.0 88.1± 13.2
BMI, kg/m2 26.5± 5.2 26.9± 5.2
% of body fat 34.2 (10.4) 34.6 (10.5)
n¼ 635
Results are presented as means (standard deviation), except for % body fat where geomet
Two Sample t-tests.performed for the inﬂammationmarkers with each other, as well as
with baseline values of obesity and other related factors (Table 3).
Hs-CRP, IL-1Ra, IL-6, TNF-alpha and HMW adiponectin were asso-
ciated with each obesity measure at baseline (p< 0.0001). They
were generally associated with each other apart from HMW-
adiponectin not being associated with IL-6 and TNF-alpha. Hs-
CRP, IL-1Ra and IL-6 were also strongly associated with physical
activity and level of education.
We tested for any differences in baseline inﬂammation status
between participants who had lost weight and those who had
gained weight at follow-up. In linear regression models for these
subgroups, after adjusting for age, gender and baseline BMI, we
found a modest direct association with the change in weight and
IL1-Ra (for both groups) and HMW adiponectin (weight gain
group). However, hs-CRP, IL-6 and TNF-alpha were not associated
with the change in weight in this subgroup analysis.
3.2. Longitudinal analyses
Hs-CRP and IL-1Ra levels had a modest inverse association with
changes in weight, in BMI, in waist circumference and in % body fat
(Model 2, p< 0.001) (Table 4). However, this association dis-
appeared after adjustment for baseline BMI.
In all models, IL-6 and TNF-alpha had largely non-signiﬁcant
inverse associations with each of the outcome variables (change
in weight, BMI, waist circumference and % body fat) (Table 4).
HMW adiponectin was associated with a small but statistically
signiﬁcant (p< 0.001) increase in the changes in weight, BMI and
waist circumference in models 1 and 2. These modest changes
remained statistically signiﬁcant after adjustment for baseline BMI
(model 3) for changes in weight (p¼ 0.008), BMI (p¼ 0.007) and
waist circumference (p¼ 0.002). Although HMWadiponectin had a
small associationwith changes in % body fat inmodels 1 (p¼ 0.005)
and 2 (p¼ 0.014), the statistical signiﬁcance did not persist in
model 3.
We also ran logistic regression models for hs-CRP with BMI cut-
off points at 30 kg/m2 and 10% of weight gain during the 7 years
follow-up. However, these analyses produced similar, non-
signiﬁcant results. Furthermore, ex-smokers, current smokers and
never smokers were also analysed separately with linear regression
models for hs-CRP with no signiﬁcant difference in results.
In order to establish whether study participants whose weight
increased also experienced an increase in their inﬂammation sta-
tus, we conducted a subgroup analysis (n¼ 1158) for those that
showed increased and those that showed decreased levels of hs-
CRP at follow-up. In linear regression models, after adjusting for
age, gender and baseline BMI, we found no association with the
change in inﬂammation status, represented by change in hs-CRP,
and the change in weight at follow-up.
4. Discussion
This is the ﬁrst prospective cohort study among adultsp value Men at baseline (n¼ 1533) Men at follow-up p value
0.025 82.9± 13.1 83.3± 13.4 0.17
<0.001 95.8± 11.3 98.0± 11.0 <0.001
0.035 26.9± 3.8 27.1± 3.9 0.156
0.213 23.6 (7.9) 23.3 (7.3) 0.415
n¼ 478
ric mean (interquartile range IQR) is reported; p values represent results of Welch's
Table 3
Regression analysis (b-coefﬁcients per SD) examining the association of inﬂammationmarkers with each other andwith baseline values of obesity and related factors, adjusted
for age and sex.
hs-CRP IL-1Ra IL-6 TNF-a HMW adiponectin
Height (cm) 0.008* 0.008* 0.005 0.001 0.003
Weight (kg) 0.027** 0.034** 0.008** 0.007** 0.012**
Waist circumference (cm) 0.035** 0.044** 0.011** 0.009** 0.017**
Hip circumference (cm) 0.041** 0.051** 0.013** 0.010** 0.015**
BMI (kg/m2) 0.090** 0.111** 0.028** 0.022** 0.040**
% body fat 0.063** 0.077** 0.018** 0.016** 0.028**
Energy intake (kJ/day) 0.000 0.000 0.000 0.000 0.000
Smoking status 0.073** 0.098** 0.017 0.039 0.004
Educational level 0.069∧ 0.100** 0.097** 0.028 0.011
Physical activity 0.229** 0.317** 0.110** 0.082* 0.036
Alcohol consumption (g/week) 0.000 0.000 0.000 0.000 0.001**
Systolic blood pressure (mmHg) 0.005** 0.007** 0.003∧ 0.002 0.003*
Diastolic blood pressure (mmHg) 0.009** 0.015** 0.003 0.003 0.007**
Total cholesterol (mmol/l) 0.036 0.007 0.017 0.002 0.030
HDL (mmol/l) 0.432** 0.903** 0.154∧ 0.285** 1.016**
Triglycerides (mmol/l) 0.261** 0.437** 0.057 0.133** 0.276**
HMW adiponectin (ng/ml) 0.111** 0.250** 0.008 0.038 e
TNF-a (ng/l) 0.136** 0.172** 0.282** e e
IL-6 (ng/l) 0.241** 0.158** e e e
IL-1Ra (pg/ml) 0.451** e e e e
∧<0.01, *<0.001, **<0.0001, n ranges from 3256 to 3348 depending on variable.
Table 4
Results (b-coefﬁcients per SD) of linear regression models with outcome variables: change in weight (kg), change in waist circumference (cm) and change in % body fat during
the 7-year follow-up.
n Model 1 p value for model 1 n Model 2 p value for model 2 n Model 3 p value for model 3
High-sensitivity C-reactive protein, mg/l
Change in weight 3289 0.3276 <0.001 3158 0.334 <0.001 3157 0.0167 0.877
Change in BMI 3289 0.1195 <0.001 3158 0.1236 <0.001 3157 0.0091 0.812
Change in waist circumference 3198 0.5311 <0.001 3072 0.5377 <0.001 3071 0.1424 0.274
Change in %body fat 1095 0.344 <0.001 1057 0.3702 <0.001 1056 0.1245 0.264
Interleukin-1Ra, pg/ml
Change in weight 3264 0.3193 <0.001 3136 0.3722 <0.001 3135 0.0294 0.792
Change in BMI 3264 0.1137 <0.001 3136 0.1333 <0.001 3135 0.0076 0.847
Change in waist circumference 3174 0.5934 <0.001 3051 0.6323 <0.001 3050 0.1965 0.149
Change in %body fat 1092 0.3501 <0.001 1055 0.4005 <0.001 1054 0.0619 0.597
Interleukin-6, ng/l
Change in weight 3233 0.1512 0.119 3103 0.1166 0.240 3102 0.0173 0.862
Change in BMI 3233 0.0595 0.147 3103 0.0471 0.182 3102 0.1105 0.753
Change in waist circumference 3142 0.179 0.129 3017 0.1316 0.274 3016 0.0051 0.966
Change in % body fat 1081 0.2042 0.048 1043 0.2152 0.043 1042 0.1366 0.192
Tumor necrosis factor alpha, ng/l
Change in weight 3274 0.1939 0.048 3143 0.1873 0.061 3142 0.1176 0.236
Change in BMI 3274 0.0676 0.053 3143 0.0655 0.065 3142 0.0402 0.255
Change in waist circumference 3183 0.1107 0.353 3057 0.077 0.525 3056 0.0063 0.956
Change in % body fat 1091 0.0906 0.384 1053 0.0888 0.405 1052 0.0154 0.883
HMW adiponectin, ng/ml
Change in weight 3294 0.5066 <0.001 3163 0.4565 <0.001 3162 0.2895 0.008
Change in BMI 3294 0.1816 <0.001 3163 0.1652 <0.001 3162 0.1046 0.007
Change in waist circumference 3203 0.6726 <0.001 3077 0.6377 <0.001 3076 0.4125 0.002
Change in %body fat 1098 0.3067 0.005 1060 0.2768 0.014 1059 0.1401 0.214
Model 1: Adjusted for age and sex; Model 2: Model 1 further adjusted for education status, smoking, weekly alcohol intake, daily total energy intake, leisure time physical
activity; Model 3: Model 2 further adjusted for baseline BMI. Inﬂammation markers were log-transformed for the analysis.
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on multiple indicators of obesity development, controlling for
established confounding factors. Contrary to our expectations, it
was lower levels of hs-CRP and IL-1Ra and higher levels of HMW
adiponectin that seemed to predict gains in obesity indicators. And
after adjusting themultivariatemodels for baseline BMI, we did not
see any signiﬁcant associations with our outcomes i.e. changes in
obesity indicators.
Results from the ARIC study in 2003 suggested that a mild
chronic systemic inﬂammatory state predicted weight gain in
people who quit smoking [18]. Similarly, signiﬁcant associations of
higher levels of ﬁbrinogen and CRP with large annual weight gainhave been shown in new smoking quitters [10]. Our results looking
at hs-CRP in different smoker categories did not support these
ﬁndings.
Our ﬁndings are of interest because a clear relationship exists
between obesity, insulin resistance and type II diabetes. There is
also a current understanding that inﬂammation leads to impaired
insulin action, and inﬂammation has been shown to predict both
insulin resistance and type II diabetes [19,20]. Although inﬂam-
mation plays a central role in obesity-induced conditions, its
contribution to weight gain or the development of obesity seems to
be virtually non-existent.
We are not aware of follow-up studies, which would have
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weight gain. However, studies have examined whether weight loss
decreases the levels of inﬂammation markers. Askarpour and col-
leagues recently carried out a meta-analysis of studies examining
weight reduction and inﬂammation after bariatric surgery [21].
They showed that, on average, the weight reduction was accom-
panied by clear decreases in the levels of inﬂammation markers.
Recent studies exploring the causality between inﬂammatory
markers and obesity indicators seem to be consistent with our
ﬁndings. A study using a reciprocal Mendelian randomization
design to analyse a Danish adult population concluded CRP to be a
marker of elevated adiposity rather than a driver of BMI [22].
Similarly, recent work using UK biobank data and based on the
Mendelian randomization design found chronic inﬂammation to be
a consequence rather than a cause of obesity [23].
4.1. Strengths and limitations
This study has several strengths. A large population-based
random sample of 25 to 75-year-old adults, 7-year prospective
follow-up, and high participation rate both at baseline and follow-
up. Analyses were controlled for traditional risk factors for weight
gain, other factors that may affect inﬂammation marker levels and
baseline BMI.
The main limitationwas that we could not invite all participants
for the physical re-examination. Despite the validation of self-
measurements against the nurse measurements at follow-up,
there may still be a bias in the reporting of these values. Self-
reported smoking status, alcohol use, total energy intake and the
level of physical activity may also be biased due to self-reports.
Furthermore, the baseline study participants that dropped out
from the follow-up, were slightly younger and heavier and had
modestly more elevated levels of inﬂammation markers as
compared to the ﬁnal study population. It is, however, unlikely that
the associations between the weight change and inﬂammation
markers would differ substantially between the participants and
non-participants of the follow-up study. Finally, although hs-CRP
measurements were available from samples of participants who
attended the re-examination at follow-up, we did not have follow-
up data on the other inﬂammation markers.
5. Conclusion
Our study suggests that low-grade inﬂammation, exempliﬁed as
increased levels of hs-CRP, IL-1Ra, IL-6, TNF-alpha and decreased
levels of HMW adiponectin, does not predict future weight gain or
changes in other indicators of obesity. Inﬂammation seems to be
rather a consequence of increase in weight and accumulation of
adipose tissue, especially around the waist. Its role amongst many
other factors in the complex set of metabolic and cardiovascular
disorders, smoking, mental health and other chronic illnesses vis-
a-vis obesity remains still somewhat unclear. Further prospective
studies using well-deﬁned and professionally measured contin-
uous values as well as solid linkages to health registers will be
needed to conﬁrmwhether inﬂammation has any role to play in the
development of obesity.
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